Lewis T Williams
CIK 1475714 · Executive Chairman · last filed 2026-02-18
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
FPRX price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
SUITE 140
NEWARK, CA 94560
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| PTGX | Director | 25,825 | $128.75 | $3.32M | -$1.48M | 11 | 2026-02-18 |
| Arcellx, Inc. (ACLX) Delisted | Director | 2,095,114 | $115.07 | $241.08M | $0 | 1 | 2022-02-09 |
| Neurogene Inc. (NLTX) Delisted | Director | — | $13.96 | — | $0 | 3 | 2021-05-13 |
| FIVE PRIME THERAPEUTICS, INC. (XLRN) Delisted | Director | 455,336 | $178.75 | $81.39M | -$1.51M | 19 | 2019-09-04 |
| FIVE PRIME THERAPEUTICS, INC. (FPRX) Delisted | President, CEO and Chairman | 421,828 | $38.00 | $16.03M | -$13.49M | 20 | 2016-05-13 |
| BEC | Director | 1,372 | $10.94 | $15.0K | $0 | 14 | 2011-06-22 |
Recent Filings · Page 5 of 7
70 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2016-03-31 | FIVE PRIME THERAPEUTICS, INC. (FPRX) Delisted | Mixed | — | -$770.5K | EDGAR |
| 2016-03-03 | FIVE PRIME THERAPEUTICS, INC. (FPRX) Delisted | Mixed | — | -$677.3K | EDGAR |
| 2016-02-08 | FIVE PRIME THERAPEUTICS, INC. (FPRX) Delisted | Mixed | — | -$2.05M | EDGAR |
| 2015-12-28 | FIVE PRIME THERAPEUTICS, INC. (FPRX) Delisted | Gift (G) | −953 | $0 | EDGAR |
| 2015-11-18 | FIVE PRIME THERAPEUTICS, INC. (FPRX) Delisted | Grant (A) | +50,000 | $0 | EDGAR |
| 2015-10-26 | FIVE PRIME THERAPEUTICS, INC. (FPRX) Delisted | Gift (G) | −3,337 | $0 | EDGAR |
| 2015-10-19 | FIVE PRIME THERAPEUTICS, INC. (FPRX) Delisted | Sell (S) | −72,352 | -$1.97M | EDGAR |
| 2015-09-23 | FIVE PRIME THERAPEUTICS, INC. (FPRX) Delisted | Sell (S) | −2,648 | -$58.4K | EDGAR |
| 2015-08-21 | FIVE PRIME THERAPEUTICS, INC. (FPRX) Delisted | Grant (A) | +75,000 | $0 | EDGAR |
| 2015-08-19 | FIVE PRIME THERAPEUTICS, INC. (FPRX) Delisted | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.